Cyteir Therapeutics, Inc. (CYT)

NASDAQ: CYT · IEX Real-Time Price · USD
5.63
-0.43 (-7.10%)
Jan 27, 2022 4:00 PM EST - Market closed
Market Cap199.14M
Revenue (ttm)n/a
Net Income (ttm)-35.67M
Shares Out35.37M
EPS (ttm)-3.20
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume76,735
Open6.06
Previous Close6.06
Day's Range5.50 - 6.22
52-Week Range5.40 - 23.10
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About CYT

Cyteir Therapeutics, Inc. operates as a clinical-stage oncology company that develops novel therapeutics based on the biology of DNA repair for the treatment of cancer and synthetic lethality therapeutics for autoimmune diseases. The company engages in manufacturing therapeutics that provide precision targeting of key DNA repair factors to induce diseased cells to self-destruct by DNA damage overload and uses an integrated drug development platform that modulates the imbalance between DNA damage and repair for the therapeutic effect to deliver ...

IndustryBiotechnology
IPO DateJun 18, 2021
Employees22
Stock ExchangeNASDAQ
Ticker SymbolCYT
Full Company Profile

Financial Performance

Financial Statements

News

Cyteir Therapeutics Announces First Patient Dosed in Phase 1 Combination Trial With CYT-0851

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, to...

2 weeks ago - Business Wire

Cyteir Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, an...

3 weeks ago - Business Wire

Cyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to Board of Directors

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, tod...

1 month ago - Business Wire

Cyteir Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, to...

2 months ago - Business Wire

Cyteir Therapeutics to Participate in the Credit Suisse 30th Annual Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, an...

2 months ago - Business Wire

Cyteir Therapeutics Selected to Join Russell 2000® Index

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer was...

4 months ago - Business Wire

Cyteir Therapeutics to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, an...

4 months ago - Business Wire

Cyteir Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, to...

5 months ago - Business Wire

Cyteir Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, an...

5 months ago - Business Wire

Cyteir Therapeutics Announces Closing of Initial Public Offering

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, to...

7 months ago - Business Wire

Cyteir Therapeutics Announces Pricing of Initial Public Offering

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, to...

7 months ago - Business Wire